{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(3)"],"submitter":["Kim WS"],"funding":["Regeneron Pharmaceuticals"],"pubmed_abstract":["The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients received intravenous odronextamab in 21-day cycles until progression or unacceptable toxicity, with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS) risk. The primary endpoint was objective response rate (ORR). Secondary endpoints included complete response (CR) rate, duration of response, progression-free survival (PFS) and overall survival. A total of 127 patients were enrolled. At the 29.9-month efficacy follow-up, the ORR was 52.0% and CR rate was 31.5%. Median durations of res"],"journal":["Nature cancer"],"pagination":["528-539"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12003196"],"repository":["biostudies-literature"],"pubmed_title":["Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial."],"pmcid":["PMC12003196"],"pubmed_authors":["Rossi F","Cunningham D","Zhang H","Poon LM","Zhang M","Carpio C","Miqueleiz S","Zhang Q","Venugopal P","Ke X","Kim WS","Uchida T","Magnano L","Alonso A","Jin J","Wrobel T","Chong G","Gutierrez A","Kuroda J","He P","Thieblemont C","Ogawa Y","Ong SY","ELM-2 Investigators","Hsieh WS","Rok Do Y","Flenghi L","Jimenez-Ubieto A","Gonzalez-Barca E","Lech-Maranda E","Bouabdballah K","Cao J","Wu SJ","Coello AP","Farooq U","Yi S","Taszner M","Wei Z","Shariff S","Skert C","Bai O","Damaj GL","Arnason J","Chu M","Bachy E","Ibrahimi S","Jandl T","Oh SY","Eom HS","Nakamae H","Yoshida I","Prince HM","Qian W","Zhu J","Klein A","Ufkin M","Jo T","Kuhnl A","Jagadeesh D","Kim TM","Knopinska-Posluszny W","Luminari S","Huang H","Ambati S","Tobai T","Tsukasaki K","Chen TY","Tan TD","Villasboas JC","Jo JC","Brouwer-Visser J","Kim BS","Keating MM","Battistini R","La Rosee PG","Chen Y","Elmusharaf N","Capochiani E","Ayyappan S","Cordoba R","Minami Y","Li C","Li D","Takeuchi M","Vaidya R","Yamamoto R","Kim JS","Delwail V","Iskierka-Jazdzewska E","Wang MC","Gao L","Robak T","Lewis D","Chaudhry A","Nagai H","Zou L","Tucker D","Jarque I","Cai J","Walewski J","Andreu R","Mun YC","Awan F","Zilioli V","Tani M","Ganju V","Bagnato L","Yuda J","Song Y","Yeh SP","Morschhauser F","Yamauchi N","Rose H","Cho SG","Haioun C","Mohamed H","Duell J","Martin A","Stevens D","Ishizawa K","Leslie L","Lim F","Hebart H","Allan J","Weber T","Suehiro Y","Choquet S","Zinzani PL","Tessoulin B","Brociner M","Gaidano G"],"additional_accession":[]},"is_claimable":false,"name":"Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.","description":"The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients received intravenous odronextamab in 21-day cycles until progression or unacceptable toxicity, with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS) risk. The primary endpoint was objective response rate (ORR). Secondary endpoints included complete response (CR) rate, duration of response, progression-free survival (PFS) and overall survival. A total of 127 patients were enrolled. At the 29.9-month efficacy follow-up, the ORR was 52.0% and CR rate was 31.5%. Median durations of res","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-01T14:48:58.47Z","creation":"2026-04-08T13:31:08.217Z"},"accession":"S-EPMC12003196","cross_references":{"pubmed":["40097657"],"doi":["10.1038/s43018-025-00921-6"]}}